GeoVax Labs (GOVX) Common Equity (2010 - 2026)
GeoVax Labs (GOVX) posted quarterly Common Equity of $1.8 million for Q2 2026, down 37.59% year-over-year from $2.8 million in Q2 2025, and down 53.97% quarter-over-quarter from $3.8 million in Q4 2025.
GeoVax Labs (GOVX) Common Equity (2010 - 2026) Analysis & Trends
GeoVax Labs (GOVX) has reported Common Equity for 17 consecutive years, with $1.8 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Common Equity fell 37.59% year-over-year to $1.8 million; the TTM figure through Jun 2026 stood at $1.8 million (down 37.59% YoY), while the FY2025 annual figure was $3.8 million, down 24.23% from the prior year.
- Common Equity fell to $1.8 million in Q2 2026 per GOVX's latest filing, from $3.8 million in the prior quarter.
- Across five years, Common Equity topped out at $31.8 million in Q3 2022 and bottomed at -$2.3 million in Q2 2024.
- Historically, Common Equity has averaged $10.9 million across 5 years, with a median of $7.9 million in 2025.
- Annual changes were most pronounced in 2024 — Common Equity tumbled 113.45% — and 2025, when it surged 14451.87%.
- GeoVax Labs' Common Equity stood at $26.6 million in 2022, then plunged by 78.33% to $5.8 million in 2023, then fell by 12.4% to $5.0 million in 2024, then retreated by 24.23% to $3.8 million in 2025, then plunged by 53.97% to $1.8 million in 2026.
- Business Quant data shows GOVX's Common Equity at $1.8 million in Q2 2026, $3.8 million in Q4 2025, and $4.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.72 Bn | 77.73 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.93 Bn | 59.75 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.97 Bn | 36.87 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.22 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 27.98 Bn | 9.59 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 9.79 Bn |
| 10 | GeoVax Labs | 2.88 Mn | -267,341.61 | - | 1.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.76 Mn |
| Dec 31, 2025 | 3.83 Mn |
| Sep 30, 2025 | 4.91 Mn |
| Jun 30, 2025 | 2.82 Mn |
| Mar 31, 2025 | 7.90 Mn |
| Dec 31, 2024 | 5.05 Mn |
| Sep 30, 2024 | 8.50 Mn |
| Jun 30, 2024 | -2.31 Mn |
| Mar 31, 2024 | 54,275.00 |
| Dec 31, 2023 | 5.76 Mn |
| Sep 30, 2023 | 9.12 Mn |
| Jun 30, 2023 | 17.16 Mn |
| Mar 31, 2023 | 22.87 Mn |
| Dec 31, 2022 | 26.60 Mn |
| Sep 30, 2022 | 31.78 Mn |
| Jun 30, 2022 | 27.87 Mn |
| Mar 31, 2022 | 11.35 Mn |
| Dec 31, 2021 | 4.36 Mn |
| Sep 30, 2021 | 18.00 Mn |
| Jun 30, 2021 | 19.46 Mn |